7-Hydroxymitragynine (7-OH): Pharmacology, Dependence, Product Testing & Legal Status (2026)

Important Safety Notice
This page is an educational evidence review, not a dosing, withdrawal-treatment, or legal-evasion guide. Concentrated or enhanced 7-hydroxymitragynine (7-OH) products can produce opioid-like intoxication, dependence, withdrawal, and respiratory toxicity. FDA advises consumers to avoid 7-OH products and states that enhanced 7-OH is not lawful as a dietary-supplement ingredient or conventional-food ingredient. If someone cannot be awakened, is breathing slowly or irregularly, or has another suspected opioid emergency, emergency medical care is appropriate.

---

Bottom line

7-Hydroxymitragynine is not simply “strong kratom.” It is a potent mu-opioid-receptor-active alkaloid that occurs naturally only in small amounts in kratom leaf but is now sold in products containing far higher or semi-synthetically generated concentrations.

The 2026 evidence picture is materially different from even a year ago:

• newer human-receptor assays confirm high-affinity MOR binding and multi-opioid-receptor activity;
• a peer-reviewed rat study directly demonstrated naloxone-reversible respiratory depression from intravenous 7-OH under controlled laboratory conditions;
• analytical studies show some commercial products contain elevated or semi-synthetic 7-OH inconsistent with ordinary leaf, with label-to-assay mismatches and additional unidentified or oxidation-related constituents;
• human case reports and a nine-patient series document 7-OH use disorder and opioid-like withdrawal;
• U.S. poison centers reported a sharp rise in 7-OH exposure calls during the first half of 2026;
• the American College of Medical Toxicology issued an August 2026 position statement describing opioid-like intoxication, respiratory depression, dependence, and withdrawal as clinical concerns;
• DEA opened a federal temporary-scheduling process in July 2026, while several states already apply stricter rules.

What is still missing is equally important: there are no large controlled human efficacy trials of isolated 7-OH, no FDA-approved therapeutic indication, no validated consumer dose, and no robust long-term human safety database.

---

Evidence at a glance

---

Traditional kratom leaf and concentrated 7-OH are different evidence categories

A recurring source of confusion is treating any product associated with Mitragyna speciosa as if it were pharmacologically equivalent.

FDA's scientific assessment notes that ordinary botanical kratom typically contains far less 7-OH than the enhanced products now marketed in tablets, shots, gummies, powders, and similar forms. FDA scientific assessment

Evidence-transfer rule: a human study using dried kratom leaf cannot be cited as if it directly established the pharmacokinetics, safety, or effects of a purified or enriched 7-OH tablet.

---

Receptor pharmacology: potent opioid activity is not speculative

7-OH has substantially stronger mu-opioid-receptor activity than mitragynine in commonly cited receptor assays. Obeng 2021

A 2026 study expanded this work across cloned human mu-, kappa-, and delta-opioid receptors using binding and multiple functional assays. In that experimental system, 7-OH showed high affinity for hMOR (reported Ki 15.1 ± 3.7 nM) and measurable activity at the other opioid-receptor subtypes. PMID 41924140 The important inference is receptor-level opioid pharmacology—not a milligram-for-milligram prediction of effects in a person.

Mitragynine can also be metabolically converted to 7-OH, which contributed to analgesic effects in preclinical models. Kruegel 2019

That creates two very different exposure scenarios:

1. Botanical exposure: mitragynine and many other alkaloids are consumed, with some 7-OH already present and additional 7-OH potentially formed metabolically.
2. Enhanced-product exposure: comparatively large amounts of 7-OH may be delivered directly, bypassing the need to generate that exposure from ordinary leaf chemistry and metabolism.

Receptor potency does not by itself predict an exact overdose threshold in a particular person. It does, however, make concentrated 7-OH fundamentally inappropriate to describe as just another mild botanical constituent.

---

Respiratory depression: direct evidence exists, but it is preclinical

A 2025 peer-reviewed study measured breathing in awake male and female Sprague-Dawley rats after intravenous administration. 7-OH reduced breathing frequency, tidal volume, and minute ventilation; naloxone reversed the respiratory-depressant effect. In that specific rat IV model, the potency estimate for a 50% reduction in minute volume was about 4.5-fold greater for 7-OH than morphine. PMID 41106041

That is unusually direct evidence for the respiratory-toxicity question, but the directness has strict boundaries:

• species: rats, not humans;
• route: intravenous laboratory administration, not a retail oral product;
• outcome: acute respiratory physiology, not population overdose incidence;
• comparator: morphine in the same model, not a consumer potency conversion;
• it does not establish a human “safe,” toxic, or lethal dose.

The study therefore strengthens the biological basis for respiratory-risk warnings without supplying a consumer dosing threshold. The authors declared no conflicts of interest. PubMed

---

Human evidence changed in 2026: dependence and withdrawal are now directly described

Earlier reviews correctly emphasized the lack of controlled human studies. That remains true for efficacy, but the statement that human evidence is essentially absent is no longer accurate.

Published withdrawal and use-disorder cases

Multiple clinical reports describe people using concentrated 7-OH who developed tolerance, opioid-like withdrawal, and use-disorder patterns after repeated use. PMID 41690384 PMID 41875249 PMID 40758956

The reported symptom patterns included combinations of gastrointestinal distress, restlessness, sweating/chills, anxiety, insomnia, muscle symptoms, and objective Clinical Opiate Withdrawal Scale findings.

These are case reports. They cannot tell us the population incidence of dependence, define a safe exposure, or establish one standard treatment protocol. They do provide direct human evidence that concentrated 7-OH can be associated with clinically significant opioid-like dependence and withdrawal.

Nine-patient retrospective series

A 2026 retrospective case series described nine patients with problematic purified-7-OH use seen in an addiction-medicine setting. Clinicians used buprenorphine-based care, and most patients were successfully stabilized with symptom improvement during follow-up. PMID 42225057

The useful conclusion is not a DIY withdrawal protocol. It is that clinicians are encountering a recognizable 7-OH-related use-disorder phenotype and are adapting established opioid-use-disorder care to it while formal guidance remains limited.

August 2026 medical-toxicology position statement

The American College of Medical Toxicology (ACMT) approved a position statement in August 2026 stating that clinical experience associates 7-OH with opioid-like intoxication, respiratory depression, dependence, and withdrawal; it also notes overdose/death reports involving concentrated products and says there are currently no proven therapeutic benefits for 7-OH or other kratom-associated compounds. ACMT calls for additional clinical research. ACMT position statement

A professional-society position statement is not a randomized clinical trial. It is most useful here as a synthesis of medical-toxicology experience and a safety-policy signal, not as proof of incidence or comparative risk.

---

Poison-center data show rapidly increasing real-world exposure

America's Poison Centers reported 593 7-OH exposures in 2025 and 901 exposures from January 1 through June 30, 2026. It reported that, among cases involving 7-OH alone, 38.8% had serious health problems, 63.8% were treated at a healthcare facility, and 20.5% were hospitalized. America's Poison Centers

These data deserve careful interpretation:

• poison-center calls are not a random sample of all users;
• they cannot estimate the percentage of all users who develop toxicity;
• co-exposure and product-identity issues can complicate some cases;
• reporting practices change over time.

But they are meaningful surveillance evidence that clinically important exposures are increasing—not evidence that enhanced 7-OH is merely a niche laboratory concern.

---

Commercial-product chemistry: “kratom” on a label does not prove botanical equivalence

Two recent analytical studies substantially strengthen the product-quality evidence.

Elevated products sold under the kratom umbrella

Brown and colleagues found very high 7-OH concentrations in analyzed commercial products, chromatographic profiles inconsistent with native kratom leaf, and additional unidentified peaks. The authors concluded that the studied products were chemically distinct from authentic leaf and consistent with synthetic alteration rather than ordinary botanical extraction. PMID 41065466

This is a product-sample study, not a census of the entire market. It directly supports claims about the tested products and about the need to distinguish leaf from highly altered 7-OH material.

Label-to-assay mismatch and semi-synthetic signatures

Avula and colleagues reported substantial inconsistencies between labeled and measured 7-OH in several products. Their analysis indicated a semi-synthetic origin in more than 98% of the 7-OH-labeled products they examined and identified oxidation-related byproducts. The same paper observed degradation to 3-dehydromitragynine under simulated gastric conditions. PMID 41825819

The simulated-gastric finding is laboratory chemistry, not proof that a particular degradation product causes clinical toxicity in humans. It should not be upgraded into a human-harm claim without direct toxicology data.

The practical evidence point is narrower: a consumer cannot reliably infer exposure or purity from branding alone when product identity, enrichment, transformation, or labeling may differ from the botanical source.

---

Safety: what is established versus what remains uncertain

Dependence and withdrawal

Human 2026 reports make this a documented clinical concern, not just an extrapolation from receptor pharmacology.

Respiratory depression and overdose risk

Direct rat evidence now demonstrates naloxone-reversible respiratory depression from 7-OH, while FDA and ACMT identify respiratory depression as a central safety concern. PMID 41106041 FDA ACMT

The precise respiratory risk of a particular retail product cannot be predicted from one receptor-assay number or one animal potency comparison, especially when product composition may be unreliable.

Polysubstance context

Other CNS depressants are common confounders in toxicology and mortality interpretation, and undisclosed constituents can further complicate attribution. This page therefore does not treat every kratom-associated adverse event as a clean isolated-7-OH experiment.

Long-term organ toxicity

Human long-term toxicology is inadequate. Narrow in-vitro, in-silico, or product-specific toxicology findings do not establish overall long-term safety, dependence safety, cardiopulmonary safety, or safety of commercial 7-OH products in humans.

---

Funding, conflicts, and evidence-concentration audit

Evidence-concentration warning: much of the direct human 7-OH literature is still a small collection of case reports and one small retrospective treatment series. Repeating those papers across reviews does not create a large independent clinical evidence base.

---

U.S. legal and regulatory status — verified August 22, 2026

This section is date-stamped because federal and state rules are changing quickly. It is a research snapshot, not legal advice.

FDA: product-law position is separate from CSA scheduling

FDA states that products with added or enhanced 7-OH are not lawful as dietary supplements or conventional-food ingredients, are not approved for medical use, and should be avoided. FDA has issued warning letters, pursued seizures, and published a scientific assessment describing concentrated 7-OH as an emerging opioid threat. FDA 7-OH hub

That food/drug-law position is legally distinct from whether a substance is already placed in a federal Controlled Substances Act schedule.

Federal CSA: DEA temporary-scheduling process remains the key federal action located

On July 1, 2026, DEA announced its intent to temporarily place:

• 7-OH above a specified threshold, and
• mitragynine pseudoindoxyl, MGM-15, and MGM-16

in Schedule I. The formal Notices of Intent were published in the Federal Register on July 6, 2026. 7-OH NOI DEA announcement

The proposed 7-OH threshold distinguishes ordinary botanical material from products containing elevated 7-OH and also addresses processed or synthetic material. HHS separately solicited public input on the proposed threshold.

Status precision: a Notice of Intent is not itself a temporary scheduling order. DEA's own July announcement says the CSA controls apply once the temporary scheduling orders take effect. In a fresh search through August 22, 2026, this review did not locate a later Federal Register temporary order taking effect. Accordingly, this page does not describe covered 7-OH as already federally Schedule I on that date. DEA

Selected state examples: state law is already stricter in some jurisdictions

These examples are included because a federal-only answer is now materially incomplete. They are not a 50-state survey.

Because state definitions and exceptions differ, “Is 7-OH legal in the U.S.?” no longer has one useful yes/no answer. Open retail availability is not reliable evidence of legality.

---

What the evidence does not justify

The current literature does not support:

• a therapeutic dose of isolated 7-OH;
• a “safe” recreational dose;
• converting the rat-vs-morphine respiratory potency result into a human dose conversion;
• a product-strength conversion chart;
• a withdrawal self-treatment protocol;
• assuming one retail tablet contains what its label says;
• assuming a botanical-kratom study applies to an enriched 7-OH product;
• treating simulated gastric degradation as proven human toxicity;
• assuming a product is legal merely because it is sold openly;
• assuming lack of a final federal scheduling order means FDA considers the product safe or lawful as a supplement.

---

FAQ

Is 7-OH the same as kratom?

No. 7-OH is one alkaloid associated with kratom, but ordinary leaf and deliberately enhanced 7-OH products can produce very different exposures. Treating them as interchangeable obscures both pharmacology and risk.

Does 7-OH act on opioid receptors?

Yes. Multiple in-vitro studies support mu-opioid receptor agonist activity, and a 2026 study using cloned human opioid receptors reported high-affinity hMOR binding plus activity across other opioid-receptor subtypes. That establishes receptor pharmacology, not a precise prediction of a retail product's clinical effects. PMID 41924140

Can 7-OH suppress breathing?

A 2025 peer-reviewed rat study directly found naloxone-reversible respiratory depression after intravenous 7-OH. That supports the hazard biologically, but the experiment does not establish a human oral dose threshold or quantify the risk from any particular retail tablet. PMID 41106041

Are there human clinical trials of isolated 7-OH?

No large controlled efficacy trial of isolated 7-OH was identified in this review. Human evidence now includes case reports, addiction-medicine case series, poison-center surveillance, and whole-leaf pharmacokinetic studies, but those answer different questions.

Can concentrated 7-OH cause dependence and withdrawal?

Published 2025–2026 clinical reports directly describe use disorder, tolerance, and opioid-like withdrawal associated with concentrated or purified 7-OH use. ACMT's August 2026 position statement also identifies dependence and withdrawal as clinical concerns.

Is 7-OH federally Schedule I right now?

As of this August 22, 2026 review, DEA had published Notices of Intent to temporarily schedule covered 7-OH and three related substances, but this review did not locate a later Federal Register temporary scheduling order taking effect. The federal answer does not override stricter state law. DEA

Is 7-OH legal in Tennessee?

Tennessee's HB1649/Public Chapter 950 took effect July 1, 2026 and created criminal offenses involving kratom as defined by the enacted law. That state regime must be evaluated independently of the still-moving federal scheduling process. Tennessee General Assembly

Why doesn't this page give a dose or withdrawal protocol?

Because the product market is analytically inconsistent, controlled human evidence is inadequate, opioid-like dependence is documented, respiratory toxicity is biologically credible and directly demonstrated in animals, and the purpose of this page is evidence and safety—not instructions for using or self-managing withdrawal from a high-risk substance.

---

Final verdict

The evidence now supports a stronger conclusion than older 7-OH summaries did:

7-OH has established potent opioid pharmacology, direct preclinical respiratory-depression evidence, and emerging direct human evidence of clinically significant dependence and withdrawal. Commercial products are not reliably equivalent to botanical kratom leaf, and recent analytical studies show semi-synthetic signatures, altered alkaloid profiles, and label-to-assay inconsistencies in sampled products.

At the same time, major questions remain unresolved: controlled human pharmacokinetics of purified retail-style 7-OH, dose-response relationships, long-term toxicity, product-to-product variability, population overdose incidence, and the final federal regulatory outcome.

The safest scientific framing is neither “natural kratom alkaloid” nor “fully characterized opioid.” It is an emerging, potent opioid-active substance with rapidly accumulating human safety signals, direct animal respiratory-risk evidence, substantial product-chemistry uncertainty, and a fast-changing legal environment.

Educational evidence review only. This page does not provide dosing, sourcing, preparation, drug-combination, withdrawal-treatment, or legal-evasion instructions.